Personal information

No personal information available

Activities

Collapse all

Works (15)

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights

JCO Oncology Practice
2025-02 | Journal article
DOI: 10.1200/OP-24-00547
Contributors: Igor Makhlin; Lesley Fallowfield; N. Lynn Henry; Harold J. Burstein; Mark R. Somerfield; Angela DeMichele
Source: check_circle
Crossref

Data from Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.c.7265737
Contributors: Igor Makhlin; Biniyam G. Demissei; Ralph D'Agostino; W. Greg Hundley; Camelia Baleanu-Gogonea; Nicholas S. Wilcox; Anna Chen; Amanda M. Smith; Nathaniel Sean O'Connell; James L. Januzzi et al.
Source: check_circle
Crossref

Data from Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.c.7265737.v1
Contributors: Igor Makhlin; Biniyam G. Demissei; Ralph D'Agostino; W. Greg Hundley; Camelia Baleanu-Gogonea; Nicholas S. Wilcox; Anna Chen; Amanda M. Smith; Nathaniel Sean O'Connell; James L. Januzzi et al.
Source: check_circle
Crossref

Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial

Clinical Cancer Research
2024-06-03 | Journal article
DOI: 10.1158/1078-0432.CCR-23-3952
Contributors: Igor Makhlin; Biniyam G. Demissei; Ralph D'Agostino; W. Greg Hundley; Camelia Baleanu-Gogonea; Nicholas S. Wilcox; Anna Chen; Amanda M. Smith; Nathaniel Sean O'Connell; James L. Januzzi et al.
Source: check_circle
Crossref

Supplemental Table S1 from Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956211.v1
Contributors: Igor Makhlin; Biniyam G. Demissei; Ralph D'Agostino; W. Greg Hundley; Camelia Baleanu-Gogonea; Nicholas S. Wilcox; Anna Chen; Amanda M. Smith; Nathaniel Sean O'Connell; James L. Januzzi et al.
Source: check_circle
Crossref

Supplemental Table S1 from Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956211
Contributors: Igor Makhlin; Biniyam G. Demissei; Ralph D'Agostino; W. Greg Hundley; Camelia Baleanu-Gogonea; Nicholas S. Wilcox; Anna Chen; Amanda M. Smith; Nathaniel Sean O'Connell; James L. Januzzi et al.
Source: check_circle
Crossref

Supplemental Table S2 from Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956208.v1
Contributors: Igor Makhlin; Biniyam G. Demissei; Ralph D'Agostino; W. Greg Hundley; Camelia Baleanu-Gogonea; Nicholas S. Wilcox; Anna Chen; Amanda M. Smith; Nathaniel Sean O'Connell; James L. Januzzi et al.
Source: check_circle
Crossref

Supplemental Table S2 from Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial

2024-06-03 | Preprint
DOI: 10.1158/1078-0432.25956208
Contributors: Igor Makhlin; Biniyam G. Demissei; Ralph D'Agostino; W. Greg Hundley; Camelia Baleanu-Gogonea; Nicholas S. Wilcox; Anna Chen; Amanda M. Smith; Nathaniel Sean O'Connell; James L. Januzzi et al.
Source: check_circle
Crossref

Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer

Journal of the American Heart Association
2023-06-20 | Journal article
DOI: 10.1161/JAHA.123.029361
Contributors: Michael G. Fradley; Nam H. K. Nguyen; David Madnick; Yiqing Chen; Angela DeMichele; Igor Makhlin; Susan Dent; Benedicte Lefebvre; Joseph Carver; Jenica N. Upshaw et al.
Source: check_circle
Crossref

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

npj Breast Cancer
2022-11-11 | Journal article
DOI: 10.1038/s41523-022-00487-x
Contributors: Igor Makhlin; Nicholas P. McAndrew; E. Paul Wileyto; Amy S. Clark; Robin Holmes; Lisa N. Bottalico; Clementina Mesaros; Ian A. Blair; Grace R. Jeschke; Kevin R. Fox et al.
Source: check_circle
Crossref

18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor–Positive Bone-Dominant Metastatic Breast Cancer

Radiology: Imaging Cancer
2022-11-01 | Journal article
DOI: 10.1148/rycan.220032
Contributors: Igor Makhlin; Katrina Esther Korhonen; Melissa Lynne Martin; Jennifer Gillman; Erin Schubert; Austin Ryan Pantel; David A. Mankoff; Amy S. Clark
Source: check_circle
Crossref

A Phase II Trial of the JAK-Inhibitor Ruxolitinib with Exemestane for Estrogen Receptor Positive, Aromatase Inhibitor Resistant, Advanced Breast Cancer

2022-06-01 | Preprint
DOI: 10.21203/rs.3.rs-1623128/v1
Contributors: Igor Makhlin; Nicholas McAndrew; E. Wileyto; Amy Clark; Robin Holmes; Lisa Bottalico; Clementina Mesaros; Ian Blair; Grace Jeschke; Kevin Fox et al.
Source: check_circle
Crossref

Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

Clinical Cancer Research
2021-01-15 | Journal article
DOI: 10.1158/1078-0432.CCR-20-3624
Contributors: Amy S. Clark; Igor Makhlin; Angela DeMichele
Source: check_circle
Crossref

On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress and Ongoing Challenges

Breast Cancer Management
2020-06 | Journal article
DOI: 10.2217/bmt-2020-0005
Contributors: Igor Makhlin; Angela DeMichele
Source: check_circle
Crossref

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma

CNS Oncology
2019-11-30 | Journal article
DOI: 10.2217/cns-2019-0014
Contributors: Igor Makhlin; Ryan D Salinas; Daniel Zhang; Fadi Jacob; Gou-li Ming; Hongjun Song; Deeksha Saxena; Jay F Dorsey; MacLean P Nasrallah; Jennifer JD Morrissette et al.
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for NPJ breast cancer. (1)
How many people are using ORCID?